Hierarchically sequential targeting nanoplatform suppresses NETosis-promoted angiogenesis for corneal neovascularization therapy
Journal of Controlled Release · 2026-12 · 400 · 115458
DOI: 10.1016/j.jconrel.2026.115458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-12. Verfasst von Chaoqun Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingd…. Die Arbeit nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Corneal neovascularization (CorNV) lacks effective therapies due to poor drug delivery and a complex inflammatory microenvironment, necessitating a deeper understanding of the underlying pathogenic mechanisms and the development of efficient delivery systems. Here we show that neutrophil extracellular traps (NETs) are pathologically activated in CorNV and identify peptidyl arginine deiminase 4 (PAD4) as a key therapeutic target. To achieve coordinated inhibition of NETosis and downstream vascular endothelial growth factor (VEGF) signaling, we engineer a reactive oxygen species (ROS) responsive copolymer encapsulating the PAD4 inhibitor Cl-amidine (Ca@PNH) that hierarchically targets neovascular endothelial cells and activated neutrophils via HRH and neutrophil elastase binding peptide (NEBP). Upon topical administration, Ca@PNH achieves prolonged ocular retention and lesion specific ROS triggered drug release, suppressing both NETs formation and angiogenesis. In a mouse CorNV model, this spatiotemporal strategy effectively treats neovascularization with excellent safety. Collectively, our work systematically establishes NETs as critical drivers of CorNV, identifies PAD4 as a druggable target, and offers a hierarchical delivery paradigm for inflammation driven ocular diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, 266071, China; Eye Hospital of Shandong First Medical University (…
- State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, 266071, China; Medical Science and Technology Innovation Center, S…
- State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, 266071, China; School of Life Sciences, Shandong First Medical Uni…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wei, C., Liu, X., Bi, Y., Zhao, L., Shi, J., Li, Y., Jia, K., Wang, C., & Gao, H. (2026). Hierarchically sequential targeting nanoplatform suppresses NETosis-promoted angiogenesis for corneal neovascularization therapy. Journal of Controlled Release, 400, 115458. https://doi.org/10.1016/j.jconrel.2026.115458
Vancouver
Wei C, Liu X, Bi Y, Zhao L, Shi J, Li Y, et al. Hierarchically sequential targeting nanoplatform suppresses NETosis-promoted angiogenesis for corneal neovascularization therapy. Journal of Controlled Release. 2026;400:115458. doi:10.1016/j.jconrel.2026.115458
BibTeX
@article{Wei2026,
author = {Wei, Chaoqun and Liu, Xiaoxue and Bi, Yingxuan and Zhao, Longfei and Shi, Jiahao and Li, Yifei and Jia, Kejuan and Wang, Changlong and Gao, Hua},
title = {Hierarchically sequential targeting nanoplatform suppresses NETosis-promoted angiogenesis for corneal neovascularization therapy},
journal = {Journal of Controlled Release},
year = {2026},
volume = {400},
pages = {115458},
doi = {10.1016/j.jconrel.2026.115458}
}
EUVIMED